A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and tropomyosin-related kinase (TRK) inhibitor, active against ALK inhibitor resistant tumours in preclinical studies. Here, we report the safety, toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738096/
https://www.ncbi.nlm.nih.gov/pubmed/31217479
http://dx.doi.org/10.1038/s41416-019-0503-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738096/
https://www.ncbi.nlm.nih.gov/pubmed/31217479
http://dx.doi.org/10.1038/s41416-019-0503-9

Ejemplares similares